Loading stock data…
$3.06-0.09 (-2.71%)
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform.
Wave Life Sciences Ltd. in the Healthcare sector is trading at $3.06 with a market capitalization of $1.2B. Wall Street consensus targets $18.06 (18 analysts), implying a +491.0% move over the next 12 months. The stock is currently near its 52-week low of $3.04, remaining 62.5% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 18 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.27M↓ | $38.25M↑ | $17.25M↑ | $7.61M↓ | $8.70M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$73.80M↓ | -$31.30M↑ | -$56.47M↓ | -$56.35M↓ | -$52.76M |
| Net Income | -$69.36M↓ | -$26.09M↑ | -$53.18M↑ | -$53.85M↓ | -$50.47M |
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multipl...